Drugs / BB-TL1A-VIAL-HLE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07029971 | Jun → Dec 2025 | ulcerative colitis | Vial Australia Pty Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BB-TL1A-VIAL-HLE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07029971 ↗ |
| Modality | Monoclonal antibody | “Anti-TL1A monoclonal antibody” NCT07029971 ↗ |